Pacific Shuanglin Bio pharmacy Co Ltd banner
P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 11.95 CNY -1.81%
Market Cap: ¥11.4B

Pacific Shuanglin Bio pharmacy Co Ltd
Selling, General & Administrative

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pacific Shuanglin Bio pharmacy Co Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Selling, General & Administrative
-¥433m
CAGR 3-Years
3%
CAGR 5-Years
-11%
CAGR 10-Years
-11%
Beigene Ltd
HKEX:6160
Selling, General & Administrative
-¥15.1B
CAGR 3-Years
-20%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Selling, General & Administrative
-¥6.6B
CAGR 3-Years
-25%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
RemeGen Co Ltd
SSE:688331
Selling, General & Administrative
-¥1.4B
CAGR 3-Years
-26%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Selling, General & Administrative
-¥1.7B
CAGR 3-Years
-32%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Selling, General & Administrative
-¥654m
CAGR 3-Years
-100%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
11.4B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
18.86 CNY
Undervaluation 37%
Intrinsic Value
Price ¥11.95
P

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-433m CNY

Based on the financial report for Sep 30, 2025, Pacific Shuanglin Bio pharmacy Co Ltd's Selling, General & Administrative amounts to -433m CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-11%

Over the last year, the Selling, General & Administrative growth was 7%. The average annual Selling, General & Administrative growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been 3% over the past three years , -11% over the past five years , and -11% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett